Prospects for gene therapy in Parkinson's disease

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Movement Disorders

• Publication date

  1996-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/mds.870110502PMID 8866488
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats

  2005cited by this paper
• Long-term correction of rat model of Parkinson's disease by gene therapy

  1996cited by this paper
• Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF

  1995cited by this paper
• Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain

  1995cited by this paper
• In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons

  1995cited by this paper
• Neuron saving schemes

  1995cited by this paper
• Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

  1995cited by this paper
• Gene expression from recombinant viral vectors in the central nervous system after blood-brain barrier disruption.

  1995cited by this paper
• An HSV‐1 Vector Expressing Tyrosine Hydroxylase Causes Production and Release of l‐DOPA from Cultured Rat Striatal Cells

  1995cited by this paper
• Delivery of virus-sized iron oxide particles to rodent CNS neurons.

  1994cited by this paper
• Convection-enhanced delivery of macromolecules in the brain.

  1994cited by this paper
• Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat.

  1994cited by this paper
• Gene transfer to brain using herpes simplex virus vectors

  1994cited by this paper
• Long-Term Behavioral Recovery in Parkinsonian Rats by an HSV Vector Expressing Tyrosine Hydroxylase

  1994cited by this paper
• Direct intracerebral gene transfer of an adenoviral vector expressing tyrosine hydroxylase in a rat model of Parkinson's disease

  1994cited by this paper
• Dextromethorphan: Cellular Effects Reducing Neuronal Hyperactivity

  1994cited by this paper
• Recent progress in immunoisolated cell therapy

  1994cited by this paper
• Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain

  1994cited by this paper
• Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector.

  1994cited by this paper
• Long-term increases in neurotransmitter release from neuronal cells expressing a constitutively active adenylate cyclase from a herpes simplex virus type 1 vector.

  1993cited by this paper
• Long-term correction of rat model of Parkinson's disease by gene therapy

  1993cited by this paper
• Altering central nervous system physiology with a defective herpes simplex virus vector expressing the glucose transporter gene.

  1993cited by this paper
• Transfer of a foreign gene into the brain using adenovirus vectors

  1993cited by this paper
• An adenovirus vector for gene transfer into neurons and glia in the brain

  1993cited by this paper
• A model system for in vivo gene transfer into the central nervous system using an adenoviral vector

  1993cited by this paper
• GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.

  1993cited by this paper
• Regulation of dopamine production by genetically modified primary fibroblasts

  1993cited by this paper
• Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors

  1993cited by this paper
• Introduction of a foreign gene (Escherichia coli lacZ) into rat neostriatal neurons using herpes simplex virus mutants: a light and electron microscopic study.

  1992cited by this paper
• Expression of nerve growth factor in vivo from a defective herpes simplex virus 1 vector prevents effects of axotomy on sympathetic ganglia.

  1992cited by this paper
• Expanded spectrum of viral therapy in the treatment of nervous system tumors.

  1992cited by this paper
• Intracerebral transplants of primary muscle cells: a potential 'platform' for transgene expression in the brain.

  1992cited by this paper
• Use of adeno-associated virus as a general transduction vector for mammalian cells.

  1992cited by this paper
• Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1

  1992cited by this paper
• Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes.

  1992cited by this paper
• Long-term survival of autologous muscle grafts in rat brain.

  1992cited by this paper
• Basic fibroblast growth factor protects striatal neurons in vitro from NMDA-receptor mediated excitotoxicity.

  1992cited by this paper
• Gene transfer into established and primary fibroblast cell lines: comparison of transfection methods and promoters.

  1992cited by this paper
• Morphological and neurochemical features of cultured primary skin fibroblasts of fischer 344 rats following striatal implantation

  1992cited by this paper
• Gene Transfer into Mammalian Central Nervous System Using Herpes Virus Vectors: Extended Expression of Bacterial lacZ in Neurons Using the Neuron-Specific Enolase Promoter

  1992cited by this paper
• Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa.

  1991cited by this paper
• Molecular analysis of neuronal physiology by gene transfer into neurons with herpes simplex virus vectors.

  1991cited by this paper
• Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants.

  1991cited by this paper
• Delivery of ultraviolet-inactivated 35S-herpesvirus across an osmotically modified blood-brain barrier.

  1991cited by this paper
• Experimental therapy of human glioma by means of a genetically engineered virus mutant

  1991cited by this paper
• Expression of a functional foreign gene in adult mammalian brain following in Vivo transfer via a herpes simplex virus type 1 defective viral vector.

  1991cited by this paper
• Infection of cultured striatal neurons with a defective HSV-1 vector: implications for gene therapy.

  1991cited by this paper
• Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes.

  1991cited by this paper
• The correlation between excitatory amino acid-induced current responses and excitotoxicity in striatal cultures.

  1990cited by this paper
• A latent, nonpathogenic HSV-1-derived vector stably expresses beta-galactosidase in mouse neurons.

  1990cited by this paper
• Characterization and mechanism of glutamate neurotoxicity in primary striatal cultures.

  1990cited by this paper
• Behavioural Effect of Engineered Cells that Synthesize L‐DOPA or Dopamine after Grafting into the Rat Neostriatum

  1990cited by this paper
• Transfer and expression of the lacZ gene in rat brain neurons mediated by herpes simplex virus mutants.

  1990cited by this paper
• HSV-1 vector mediated neuronal gene delivery. Strategies for molecular neuroscience and neurology.

  1990cited by this paper
• Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli beta-galactosidase.

  1990cited by this paper
• Levodopa delivery from controlled-release polymer matrix: delivery of more than 600 days in vitro and 225 days of elevated plasma levels after subcutaneous implantation in rats.

  1990cited by this paper
• Dopamine cell replacement: Parkinson's disease.

  1990cited by this paper
• Extended levodopa release from a subcutaneously implanted polymer matrix in rats

  1990cited by this paper
• Tetrahydrobiopterin-dependent production of L-dopa in NRK fibroblasts transfected with tyrosine hydroxylase cDNA: future use for intracerebral grafting.

  1990cited by this paper
• In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum.

  1990cited by this paper
• Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.

  1989cited by this paper
• Controlled release of dopamine from a polymeric brain implant: in vitro characterization.

  1989cited by this paper
• Synthesis of l‐3,4‐Bihydroxyphenylalanine by Tyrosine Hydroxylase cDNA‐Transfected C6 Cells: Application for Intracerebral Grafting

  1989cited by this paper
• Controlled release of dopamine from a polymeric brain implant: In vivo characterization

  1989cited by this paper
• Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression

  1989cited by this paper
• Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector.

  1989cited by this paper
• Chronic s.c. lisuride in Parkinson's disease--motor-performance and avoidance of psychiatric side effects.

  1988cited by this paper
• Brain-derived neurotrophic factor prevents neuronal death in vivo

  1988cited by this paper
• Herpes simplex virus virion host shutoff function

  1988cited by this paper
• Expression of four types of human tyrosine hydroxylase in COS cells

  1988cited by this paper
• Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression.

  1988cited by this paper
• The herpes simplex virus virion host shutoff function

  1988cited by this paper
• A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons.

  1988cited by this paper
• Controlled‐release levodopa/carbidopa.

  1987cited by this paper
• Motor fluctuations in Parkinson's disease: Pathogenetic and therapeutic studies

  1987cited by this paper
• Controlled‐release levodopa/carbidopa

  1987cited by this paper
• Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomal state.

  1987cited by this paper
• Alpha-1-antitrypsin (Pi) subtypes in the Spanish Basque provinces.

  1987cited by this paper
• Isolation and characterization of the human tyrosine hydroxylase gene: identification of 5' alternative splice sites responsible for multiple mRNAs.

  1987cited by this paper
• On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

  1984cited by this paper
• Site-specific cleavage/packaging of herpes simplex virus DNA and the selective maturation of nucleocapsids containing full-length viral DNA.

  1982cited by this paper
• The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector.

  1982cited by this paper
• Delivery of hexosaminidase A to the cerebrum after osmotic modification of the blood--brain barrier.

  1981cited by this paper
• Replication of herpes simplex virus DNA: localization of replication recognition signals within defective virus genomes.

  1981cited by this paper
• The decarboxylation of DOPA in the parkinsonian brain: in vivo studies on an animal model.

  1980cited by this paper
• Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA.

  1980cited by this paper
• Nonaminergic striatal neurons convert exogenous l‐dopa to dopamine in parkinsonism

  1980cited by this paper
• Global fallout of curium

  1978cited by this paper
• The Biochemical Basis of Neuropharmacology

  1975cited by this paper
• The clinical physiology of side effects in long-term L-DOPA therapy.

  1974cited by this paper
• Evidence that Neurons Harbor Latent Herpes Simplex Virus

  1974cited by this paper
• “On‐off” phenomenon with levodopa therapy in parkinsonism

  1974cited by this paper
• Recovery of herpes-simplex virus from human trigeminal ganglions.

  1973cited by this paper
• [Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].

  1969cited by this paper

• Gene therapy for Parkinson's disease

  2008influential citation
• THE DOPAMINERGIC NIGROSTRIATAL SYSTEMAND PARKINSON'S DISEASE: MOLECULAR EVENTSIN DEVELOPMENT, DISEASE, AND CELL DEATH, AND NEW THERAPEUTIC STRATEGIES

  2007cites this paper
• Gene Therapy for Parkinson's Disease

  2005cites this paper
• Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.

  2004cites this paper
• [Bone marrow stromal cells. An alternative source of restorative therapy in degenerative diseases of the central nervous system].

  2003cites this paper
• Herpes simplex virus vectors for Parkinson's disease.

  2003cites this paper
• Herpes simplex virus vectors for Parkinson's disease.

  2003cites this paper
• [Ex vivo gene therapy in the treatment of Parkinson s disease].

  2003cites this paper
• Scaling-up The Production and Purification of HSV-based Gene Therapy Vectors and Development of GLP Assay System to Analyze Quantity and Quality of Clinical-grade HSV Vector Stocks

  2002cites this paper
• Book Review: Gene Therapy with Herpes Simplex Virus Vectors: Progress and Prospects for Clinical Neuroscience

  2001cites this paper
• Gene delivery and gene therapy with herpes simplex virus-based vectors.

  2001cites this paper
• Viral Vectors for Gene Therapy in Parkinson's Disease

  2001cites this paper
• Encapsulated cell implants as a novel treatment for Parkinson's disease.

  2001cites this paper
• Viral vectors in the treatment of Parkinson's disease

  2000cites this paper
• Encapsulated neural transplants.

  2000cites this paper
• Gene Therapy Approaches to Parkinson´s Disease

  2000cites this paper
• Aktueller Stand der Gentherapie

  2000cites this paper
• Dopaminergic Dysfunction in Parkinsonism: New Lessons from Imaging

  1999cites this paper
• Astrocyte line SVG-TH grafted in a rat model of Parkinson's disease.

  1999cites this paper
• Somatic gene therapy in animal models of Parkinson's disease.

  1999cites this paper
• Advances in Research on Neurodegeneration

  1999cites this paper
• Therapeutic Potential of Nerve Growth Factors in Parkinson’s Disease

  1999cites this paper
• Strategies for Administering Neurotrophic Factors to the Central Nervous System

  1999cites this paper
• Therapeutics in the Neurorehabilitation of Parkinson's Disease

  1999cites this paper
• TREATMENT OF NEUROSURGICAL DISEASE IN THE NEW MILLENNIUM

  1999cites this paper
• New Developments in the Surgery for Parkinson's Disease

  1999cites this paper
• Restorative gene therapy approaches to Parkinson's disease.

  1999cites this paper
• Review : Gene Therapy: Applications to the Neurosciences and to Neurological Disease

  1998cites this paper
• Potential of gene therapy for Parkinson's disease: neurobiologic issues and new developments in gene transfer methodologies.

  1998cites this paper
• Application of gene therapy for Parkinson's disease: nonhuman primate experience.

  1998cites this paper
• Gene therapy for inherited neurological disorders: towards therapeutic intervention in the Lesch-Nyhan syndrome.

  1998cites this paper
• The role of neuronal growth factors in neurodegenerative disorders of the human brain.

  1998cites this paper
• Gene therapy of central nervous system tumors.

  1998cites this paper
• Adenovirus vector-mediated gene transfer into human epileptogenic brain slices: prospects for gene therapy in epilepsy.

  1997cites this paper
• Parkinson's Disease: The Case for Novel Treatment Strategies

  1997cites this paper
• Neuronal cell transplantation for Parkinson's and Huntington's diseases.

  1997cites this paper
• Direct Gene Transfer Into Human Epileptogenic Hippocampal Tissue with an Adeno‐Associated Virus Vector: Implications for a Gene Therapy Approach to Epilepsy

  1997cites this paper